The safety and efficacy of weekly paclitaxel and cisplatin chemotherapy for patients with ovarian cancer who developed carboplatin hypersensitivity reaction in previous chemotherapy.

Authors

Kyoko Nishikimi

Departments of Reproductive Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan

Kyoko Nishikimi , Shinichi Tate , Ayumu Matsuoka , Makio Shozu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Efficacy and safety of camrelizumab combined with chemotherapy (irinotecan combined with platinum) followed by camrelizumab combined with apatinib in the first-line treatment of advanced small cell lung cancer: A phase II study.

First Author: Jun Ni

insert_chart_outlined

Poster

2011 ASCO Annual Meeting

bookmark_border

The phase II study of efficacy and safety of oxaliplatin with doxorubicin in recurrent ovarian cancer (OC).

First Author: I. Pokataev

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.

First Author: Martin Reck

insert_chart_outlined

Poster

2022 ASCO Genitourinary Cancers Symposium

bookmark_border

Impact of primary tumor location on efficacy and safety of pembrolizumab (pembro) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) enrolled in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-045 trials.

First Author: Peter H. O'Donnell